What should patients taking NSAIDs be monitored for aside from kidney function?

Monitoring patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) for gastrointestinal bleeding is crucial due to the potential adverse effects these medications can have on the gastrointestinal (GI) tract. NSAIDs can irritate the stomach lining and inhibit the production of protective prostaglandins, leading to an increased risk of ulcers and gastrointestinal hemorrhage.

Given the common use of NSAIDs for pain management and inflammation, healthcare providers must remain vigilant for signs and symptoms of GI bleeding, which may include abdominal pain, dark or tarry stools, and vomiting blood. This is especially important for patients who may already have risk factors for GI complications, such as a history of peptic ulcer disease or concurrent anticoagulant therapy.

While monitoring weight fluctuations, skin reactions, and vision changes may also be relevant in specific contexts, they are not as directly associated with NSAID use nor are they universally prioritized in clinical practice compared to the risks of gastrointestinal issues. Therefore, focusing on GI bleeding is essential for patient safety and effective management during NSAID therapy.